News Releases

Date	Title and Summary	View
Jan 21, 2021	Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
Jan 19, 2021	DePuy Synthes Receives 510(k) FDA Clearance for VELYS™ Robotic-Assisted Solution Designed for Use with the ATTUNE® Total Knee System
Jan 15, 2021	DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
Jan 12, 2021	Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer’s 2020 World Conference on Lung Cancer
Jan 04, 2021	Johnson & Johnson Announces Quarterly Dividend for First Quarter 2021
Dec 28, 2020	Janssen Submits European Marketing Authorisation Application for Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dec 21, 2020	Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Dec 21, 2020	Janssen Announces European Commission Authorisation of the First Complete Long-Acting Injectable HIV Treatment in Europe
Dec 18, 2020	Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Dec 14, 2020	Johnson & Johnson to Participate in the 39th Annual J.P. Morgan Healthcare Conference